Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

107
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
107
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

133
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

108
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
108
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

123
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
123
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

279
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
279
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

611
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current epidemiological trends and in-hospital mortality of acute pancreatitis in Germany: a systematic analysis of standardized hospital discharge data between 2008 and 2017.

Zeitschrift fur Gastroenterologie·2021
Same author

Drug research·2021
Same author

Bile Acids Activate NLRP3 Inflammasome, Promoting Murine Liver Inflammation or Fibrosis in a Cell Type-Specific Manner.

Cells·2021
Same author

[The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment].

Zeitschrift fur Gastroenterologie·2021
Same author

Haemorrhagic ulcerative duodenitis in a patient with COVID-19 infection: clinical improvement following treatment with budesonide.

BMJ open gastroenterology·2021
Same author

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.

Frontiers in medicine·2021

Related Experiment Video

Updated: Dec 13, 2025

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

19.9K

[Hepatic dysfunction in sepsis].

Philipp Kasper1, Frank Tacke2, Hans-Michael Steffen3

  • 1Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland. philipp.kasper@uk-koeln.de.

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|July 30, 2020
PubMed
Summary

Sepsis frequently causes severe liver dysfunction, including hypoxic hepatitis and liver failure. Despite treatment, patient outcomes remain poor, highlighting the critical nature of sepsis-related liver injury.

Keywords:
Acute-on-chronic liver failureHypoxic hepatitisIntensive care medicineSecondary sclerosing cholangitisSepsis-induced cholestasis

More Related Videos

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.4K
Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.9K

Related Experiment Videos

Last Updated: Dec 13, 2025

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

19.9K
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.4K
Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.9K

Area of Science:

  • Hepatology
  • Critical Care Medicine
  • Immunology

Background:

  • Sepsis, a life-threatening condition, often leads to acute liver dysfunction.
  • Systemic inflammation, immune dysregulation, and microcirculatory issues contribute to various liver problems in sepsis.
  • Secondary sclerosing cholangitis is a severe late complication in critically ill patients with sepsis.

Purpose of the Study:

  • To summarize the clinical manifestations and management of sepsis-related liver dysfunction.
  • To highlight the poor prognosis associated with severe hepatic dysfunction in sepsis patients.

Main Methods:

  • Review of clinical presentations of liver dysfunction in sepsis.
  • Discussion of management strategies for sepsis-induced liver injury.
  • Analysis of patient outcomes in sepsis with severe hepatic dysfunction.

Main Results:

  • Sepsis can cause hypoxic hepatitis, sepsis-associated cholestasis, and liver failure.
  • Effective management involves prompt infection treatment, hemodynamic stabilization, and optimized oxygen delivery.
  • Despite interventions, outcomes for patients with severe sepsis and liver dysfunction are often poor.

Conclusions:

  • Sepsis-induced liver dysfunction is a serious complication with significant morbidity and mortality.
  • Current management strategies, while crucial, do not sufficiently improve outcomes in severe cases.
  • Further research is needed to improve the prognosis of sepsis patients with liver compromise.